Literature DB >> 17078249

Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs.

Danny W Scott1, Jeanine Peters, William H Miller.   

Abstract

Orbifloxacin tablets were administered orally to 23 dogs with superficial and/or deep staphylococcal pyoderma. Response to therapy was excellent in 95.6% of the dogs. Duration of therapy varied from 21 to 40 days (average 29 days) for dogs having only superficial infections, and from 25 to 150 days (average 72 days) for dogs having deep infections. Relapses occurred in 18% of the dogs within a 3-month period. One dog developed a presumed adverse cutaneous drug reaction. Under the conditions of this study, orbifloxacin was an effective, safe, and convenient antibiotic for the treatment of superficial and deep staphylococcal pyoderma in dogs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078249      PMCID: PMC1571130     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  7 in total

1.  Efficacy of clindamycin hydrochloride capsules for the treatment of deep pyoderma due to Staphylococcus intermedius infection in dogs.

Authors:  D W Scott; K E Beningo; W H Miller; E Rothstein
Journal:  Can Vet J       Date:  1998-12       Impact factor: 1.008

2.  Efficacy of cefadroxil in the treatment of bacterial dermatitis in dogs.

Authors:  D W Angarano; J M MacDonald
Journal:  J Am Vet Med Assoc       Date:  1989-01-01       Impact factor: 1.936

3.  Therapy of difficult cases of canine pyoderma with marbofloxacin: a report of 39 dogs.

Authors:  D N Carlotti; E Guaguere; D Pin; P Jasmin; E Thomas; V Guiral
Journal:  J Small Anim Pract       Date:  1999-06       Impact factor: 1.522

4.  Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.

Authors:  M Paradis; L Abbey; B Baker; M Coyne; M Hannigan; D Joffe; B Pukay; A Trettien; S Waisglass; J Wellington
Journal:  Vet Dermatol       Date:  2001-06       Impact factor: 1.589

5.  Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma.

Authors:  Patricia A Kay-Mugford; Allan J Weingarten; Maureen Ngoh; Robert Zolynas; Amy White; Terry Katz; Robert Simmons; Kanwal J Varma
Journal:  Vet Ther       Date:  2002

6.  Efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs.

Authors:  D W Scott; W H Miller; S M Cayatte; M S Bagladi
Journal:  Can Vet J       Date:  1994-10       Impact factor: 1.008

7.  A fluoroquinolone induces a novel mitogen-encoding bacteriophage in Streptococcus canis.

Authors:  Keely T Ingrey; Jun Ren; John F Prescott
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

  7 in total
  4 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.

Authors:  Elias Gebru; Joong-Su Lee; Zhi-Qiang Chang; Mi-Hyun Hwang; Henrique Cheng; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

2.  Suggested guidelines for using systemic antimicrobials in bacterial skin infections: part 2-- antimicrobial choice, treatment regimens and compliance.

Authors:  L Beco; E Guaguère; C Lorente Méndez; C Noli; T Nuttall; M Vroom
Journal:  Vet Rec       Date:  2013-02-09       Impact factor: 2.695

3.  Development and validation of a microbiological agar assay for determination of orbifloxacin in pharmaceutical preparations.

Authors:  Edith C L Cazedey; Hérida R N Salgado
Journal:  Pharmaceutics       Date:  2011-08-29       Impact factor: 6.321

4.  A new host cell internalisation pathway for SadA-expressing staphylococci triggered by excreted neurochemicals.

Authors:  Arif Luqman; Patrick Ebner; Sebastian Reichert; Peter Sass; Clement Kabagema-Bilan; Christine Heilmann; Peter Ruth; Friedrich Götz
Journal:  Cell Microbiol       Date:  2019-06-07       Impact factor: 3.715

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.